Abstract
Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Current Drug Safety
Title:Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report
Volume: 11 Issue: 3
Author(s): Hiral N. Golakiya, Hiren N. Hirapara, Sugnesh J. Parmar, Viren N. Naik and Chandrabhanu B. Tripathi
Affiliation:
Keywords: Triamcinolone acetonide, bevacizumab, intraocular pressure, diabetes mellitus, adverse drug reaction.
Abstract: Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
Export Options
About this article
Cite this article as:
Golakiya N. Hiral, Hirapara N. Hiren, Parmar J. Sugnesh, Naik N. Viren and Tripathi B. Chandrabhanu, Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report, Current Drug Safety 2016; 11 (3) . https://dx.doi.org/10.2174/1574886311666160405110246
DOI https://dx.doi.org/10.2174/1574886311666160405110246 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Application of Hydrogen in Ophthalmology
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Role of Non-Coding RNA of Human Platelet in Cardiovascular Disease
Current Medicinal Chemistry Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research Single Nucleotide Polymorphism and Serum Levels of VEGFR2 are Associated With Age Related Macular Degeneration
Current Neurovascular Research Fluocinolone Acetonide Implantable Device for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Retinal Angiomatous Proliferation
Current Drug Targets Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science